Please provide an in-depth overview of hypertension, including its definition, risk factors, evaluation, treatment, and monitoring.

Hypertension: Comprehensive Overview

Definition and Classification

Hypertension is defined as blood pressure ≥130/80 mm Hg based on an average of ≥2 careful readings obtained on ≥2 separate occasions, or when a patient is receiving antihypertensive therapy 1. This represents the most current evidence-based threshold, lowered from the historical 140/90 mm Hg standard to enable earlier intervention and reduce cardiovascular morbidity and mortality.

The classification system stratifies blood pressure into four categories 1:

• Normal: <120/<80 mm Hg
• Elevated: 120-129/<80 mm Hg
• Stage 1 Hypertension: 130-139/80-89 mm Hg
• Stage 2 Hypertension: ≥140/≥90 mm Hg

Individuals are classified according to their highest systolic or diastolic category. This classification applies to untreated adults and guides prevention and treatment decisions.

Epidemiology and Impact

Hypertension affects approximately 46.7% of U.S. adults (115.3 million people), with prevalence varying significantly by demographics 1:

• Age: 20.3% (ages 18-29) increasing to 83.7% (ages 75-80)
• Race/ethnicity: Non-Hispanic Black adults (56.8%) have the highest prevalence, followed by Hispanic (50.4%), Non-Hispanic Asian (49.8%), and Non-Hispanic White (47.0%)
• Sex: Men (49.5%) slightly higher than women (43.9%)

Hypertension is the leading preventable cause of premature death worldwide and the most prevalent modifiable cardiovascular disease risk factor 2, 1. It directly contributes to myocardial infarction, heart failure, stroke, end-stage renal disease, and all-cause mortality. African Americans bear a disproportionate burden, with earlier onset and higher rates of complications including stroke and kidney disease 3.

Accurate Blood Pressure Measurement

In-Office Measurement

Proper technique is critical to avoid misdiagnosis. The 2025 ACC/AHA guidelines emphasize 1:

• Patient should be seated quietly for 5 minutes with back supported, feet flat on floor, arm supported at heart level
• Use appropriately sized cuff (bladder encircling ≥80% of arm circumference)
• Take ≥2 readings 1-2 minutes apart and average them
• Avoid caffeine, exercise, and smoking for 30 minutes before measurement
• Empty bladder before measurement

Automated office blood pressure (AOBP) measurements can be used when performed under proper conditions, with thresholds of ≥135/85 mm Hg considered analogous to mean awake ambulatory BP ≥135/85 mm Hg 4.

Out-of-Office Monitoring

Out-of-office BP monitoring through home blood pressure monitoring (HBPM) or ambulatory blood pressure monitoring (ABPM) is essential to detect white coat hypertension and masked hypertension 5. ABPM is more sensitive for detecting masked hypertension, while HBPM is the most practical method for medication titration and long-term monitoring 5.

For HBPM, the recommended protocol is:

• Duplicate readings per occasion, twice daily (morning and evening), over 7 consecutive days (the "722 protocol") 6
• Use validated, automated upper-arm devices
• Record all readings for review with clinician

Risk Factors and Pathophysiology

Modifiable Risk Factors

• Excess dietary sodium intake
• Physical inactivity
• Obesity (BMI ≥30 kg/m²) and increased waist circumference (>102 cm men, >88 cm women)
• Excessive alcohol consumption (>14 drinks/week men, >9 drinks/week women)
• Poor diet quality (low in fruits, vegetables, whole grains)
• Chronic stress 4

Non-Modifiable Risk Factors

• Advancing age (SBP increases progressively with aging)
• Family history and genetic susceptibility
• Race/ethnicity (higher prevalence and earlier onset in Black populations)
• Male sex (until older age when prevalence equalizes) 2, 1

Pathophysiological Mechanisms

Hypertension results from increased peripheral vascular resistance with normal cardiac output in most established cases 7. Key mechanisms include:

• Vascular dysfunction: Endothelial dysfunction, arterial stiffening, increased oxidative stress
• Neurohormonal dysregulation: Overactivation of renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system hyperactivity
• Renal mechanisms: Sodium retention, impaired pressure natriuresis
• Endocrine factors: Autonomous aldosterone production (increasingly recognized even in stages 1-2 hypertension) 5
• Inflammatory processes: Chronic low-grade inflammation contributing to vascular damage 8

Diagnostic Evaluation

Initial Assessment

When hypertension is confirmed, evaluation should identify:

1. Target organ damage (eyes, heart, kidneys, brain, peripheral vessels)
2. Cardiovascular risk factors (diabetes, dyslipidemia, smoking, family history)
3. Secondary causes of hypertension
4. Comorbid conditions affecting treatment decisions

Baseline Laboratory Testing

Recommended initial tests include 9:

• Fasting lipid panel
• Fasting glucose or HbA1c
• Serum creatinine with estimated GFR
• Serum electrolytes (sodium, potassium)
• Urinalysis
• Electrocardiogram

Cardiovascular Risk Stratification

Treatment decisions should be based on absolute cardiovascular disease risk, not blood pressure alone 9. Use the ACC/AHA Pooled Cohort Equations to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk. Patients are automatically considered high-risk if they have:

• Diabetes mellitus
• Chronic kidney disease (eGFR <60 mL/min/1.73m²)
• Known cardiovascular disease
• Age ≥65 years
• 10-year ASCVD risk ≥10% 9

Secondary Hypertension Screening

Screen for secondary causes when hypertension presents with resistant hypertension, age of onset <30 years, sudden onset or worsening, severe elevation (≥180/≥110 mm Hg), or evidence of target organ damage disproportionate to duration 9, 10.

Common secondary causes to evaluate 2, 9:

• Primary aldosteronism: Check aldosterone-to-renin ratio in all patients with difficult-to-control or resistant hypertension; if ratio is elevated or renin is suppressed, measure 24-hour urine aldosterone during high sodium intake 5
• Obstructive sleep apnea: Screen with validated questionnaires (STOP-BANG); confirm with polysomnography
• Renovascular disease: Doppler ultrasound, CT angiography, or MR angiography in appropriate candidates
• Chronic kidney disease: Assess with eGFR and urinalysis
• Pheochromocytoma: Plasma or 24-hour urine metanephrines in patients with paroxysmal symptoms, resistant hypertension
• Cushing syndrome: 24-hour urine cortisol or overnight dexamethasone suppression test
• Thyroid disease: TSH measurement
• Coarctation of aorta: Blood pressure in all four extremities, imaging if discrepancy
• Drug-induced: Review all medications including NSAIDs, decongestants, stimulants, oral contraceptives, immunosuppressants, antidepressants

Treatment Approach

Treatment Thresholds and Goals

The universal blood pressure target is <130/80 mm Hg for all adults with hypertension, regardless of age or comorbidities 9, 1. This represents a paradigm shift from previous guidelines and is supported by the SPRINT trial demonstrating cardiovascular benefit from intensive BP lowering 9.

Treatment initiation thresholds 11, 9:

• Stage 1 hypertension (130-139/80-89 mm Hg):

  • High-risk patients (10-year ASCVD risk ≥10%, diabetes, CKD, known CVD, age ≥65): Initiate pharmacotherapy immediately
  • Non-high-risk patients: Lifestyle modification for 3-6 months; if BP remains elevated, initiate pharmacotherapy

• Stage 2 hypertension (≥140/≥90 mm Hg): Initiate pharmacotherapy immediately in all patients, regardless of risk

• Elevated BP (120-129/<80 mm Hg): Lifestyle modification only; reassess in 3-6 months

Lifestyle Modifications (S-ABCDE Approach)

Lifestyle modification is the cornerstone of hypertension management and should be implemented in all patients with elevated BP or hypertension 4, 5, 4. Each intervention independently lowers BP, and concurrent use produces additive effects 5.

Specific recommendations 4, 6:

• Sodium restriction:

  • ≤1500 mg/day (65 mmol) for adults ≤50 years
  • ≤1300 mg/day (57 mmol) for adults 51-70 years
  • ≤1200 mg/day (52 mmol) for adults >70 years

• Aerobic exercise: 30-60 minutes of moderate-intensity activity 4-7 days per week

• Body weight: Maintain BMI 18.5-24.9 kg/m²; waist circumference ≤102 cm (men), ≤88 cm (women)

• DASH diet: Emphasize fruits, vegetables, low-fat dairy, whole grains, plant proteins; reduce saturated fat and cholesterol

• Alcohol limitation: ≤14 standard drinks/week (men), ≤9 drinks/week (women)

• Stress management: Consider in selected individuals with hypertension

Pharmacologic Treatment

Initial Drug Selection

For adults without compelling indications, first-line therapy should include thiazide or thiazide-like diuretics, ACE inhibitors, angiotensin receptor blockers (ARBs), or long-acting calcium channel blockers (CCBs) 4, 9. Beta-blockers are appropriate for patients <60 years without other indications 4.

Key considerations for initial therapy 9:

• Thiazide-like diuretics (chlorthalidone, indapamide) are preferred over hydrochlorothiazide due to superior cardiovascular outcomes and longer duration of action
• In Black patients (including those with diabetes): Thiazide diuretics and CCBs are preferred as first-line agents; ACE inhibitors and ARBs are less effective as monotherapy 9
• Most patients will require ≥2 medications to achieve BP goal 4

Combination Therapy

For stage 2 hypertension with BP >20/10 mm Hg above goal, initiate with 2 first-line agents from different classes, preferably as a single-pill combination 4, 9. This approach:

• Improves adherence through simplified regimen
• Achieves BP control more rapidly
• Reduces cardiovascular events sooner

Recommended combinations:

• ACE inhibitor or ARB + CCB
• ACE inhibitor or ARB + thiazide diuretic
• CCB + thiazide diuretic

Avoid combining ACE inhibitors with ARBs unless compelling indications exist, as this increases adverse events without additional benefit 4.

Compelling Indications for Specific Agents

Certain comorbidities mandate specific drug classes 4, 9:

• Coronary artery disease: ACE inhibitor, ARB, or beta-blocker
• Heart failure with reduced ejection fraction: ACE inhibitor (or ARB), beta-blocker, aldosterone antagonist, diuretic
• Post-myocardial infarction: Beta-blocker, ACE inhibitor, aldosterone antagonist
• Chronic kidney disease with albuminuria: ACE inhibitor or ARB
• Diabetes mellitus: ACE inhibitor or ARB (first-line); thiazide diuretic or CCB acceptable if no albuminuria
• Cerebrovascular disease/stroke prevention: ACE inhibitor + thiazide diuretic combination preferred 4

Special Populations

Older Adults (≥65 Years)

Treatment of hypertension with an SBP goal <130 mm Hg is recommended for noninstitutionalized, ambulatory, community-dwelling adults ≥65 years with average SBP ≥130 mm Hg 9. The SPRINT trial demonstrated that intensive BP lowering in older adults:

• Reduces cardiovascular events and all-cause mortality
• May prevent or partially arrest cognitive decline 5
• Does not increase falls, syncope, or acute kidney injury 5

Asymptomatic orthostatic hypotension should not be a reason to withhold or down-titrate treatment, as it is not associated with higher rates of adverse outcomes 5.

For frail older adults with high comorbidity burden and limited life expectancy, use clinical judgment and shared decision-making to balance benefits and risks 9.

Chronic Kidney Disease

Initiate antihypertensive therapy at BP ≥130/80 mm Hg with a treatment goal <130/80 mm Hg 9. For patients with CKD and albuminuria (≥300 mg/day or albumin-to-creatinine ratio ≥300 mg/g), ACE inhibitors or ARBs are recommended as first-line therapy due to renoprotective effects 4.

Monitor serum creatinine and potassium 2-4 weeks after initiating or adjusting RAAS inhibitors; accept up to 30% increase in creatinine if stable 9.

Diabetes Mellitus

Initiate pharmacotherapy at BP ≥130/80 mm Hg with a treatment goal <130/80 mm Hg 9. ACE inhibitors or ARBs are preferred first-line agents, particularly in patients with albuminuria. The ACCORD trial, when meta-analyzed with SPRINT, supports intensive BP lowering in diabetes 9.

Pregnancy

This is addressed separately in hypertensive disorder of pregnancy guidelines. Women with chronic hypertension should be counseled about:

• Teratogenic potential of ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists (contraindicated in pregnancy)
• Benefits of low-dose aspirin starting at 12 weeks gestation in subsequent pregnancies to reduce preeclampsia risk 10

Resistant Hypertension

Resistant hypertension is defined as BP ≥130/80 mm Hg despite treatment with ≥3 antihypertensive medications from different classes at maximally tolerated doses (including a diuretic), or BP controlled but requiring ≥4 medications 5, 10. Prevalence is approximately 8.5-20% among treated hypertensive adults 10.

Evaluation Algorithm

Before diagnosing resistant hypertension, exclude pseudo-resistance 9, 10:

1. Confirm with out-of-office BP monitoring (HBPM or ABPM) to rule out white coat effect
2. Assess medication adherence (pill counts, pharmacy refill records, direct questioning)
3. Verify proper BP measurement technique (appropriate cuff size, positioning)

Management Strategy

Step 1: Optimize first-line therapy 10:

• Ensure regimen includes ACE inhibitor or ARB + CCB + thiazide-like diuretic (chlorthalidone or indapamide, not hydrochlorothiazide)
• Maximize doses to target or maximally tolerated levels

Step 2: Identify and address contributing factors 10:

• Interfering medications: NSAIDs, decongestants, stimulants, oral contraceptives, corticosteroids, immunosuppressants—discontinue or substitute when possible
• Lifestyle factors: Excess sodium intake, obesity, excessive alcohol, physical inactivity
• Obstructive sleep apnea: Screen and treat if present
• Secondary hypertension: Screen for primary aldosteronism (most common), renovascular disease, pheochromocytoma

Step 3: Add fourth-line agent 10:

In adults with uncontrolled resistant hypertension and eGFR ≥45 mL/min/1.73m², addition of a mineralocorticoid receptor antagonist (spironolactone 25-50 mg/day or eplerenone) is recommended 10. RCTs demonstrate spironolactone reduces 24-hour systolic BP by 6.6-8.7 mm Hg compared to placebo, with greater efficacy than doxazosin or bisoprolol 10.

Monitor potassium and creatinine closely (2-4 weeks after initiation, then periodically). Contraindications include hyperkalemia (K+ >5.0 mEq/L) and severe CKD (eGFR <30 mL/min/1.73m²).

Alternative fourth-line agents if mineralocorticoid antagonists are contraindicated or not tolerated:

• Alpha-blockers (doxazosin)
• Beta-blockers (if not already prescribed)
• Direct vasodilators (hydralazine)
• Central alpha-agonists (clonidine)

Step 4: Referral to hypertension specialist if BP remains uncontrolled despite above measures 9, 10.

Monitoring and Follow-Up

Initial Titration Phase

After initiating or adjusting antihypertensive therapy, reassess monthly until BP goal is achieved 9. Each visit should include:

• BP measurement (office and review of home readings)
• Assessment of adherence and barriers
• Monitoring for adverse effects
• Reinforcement of lifestyle modifications
• Laboratory monitoring (electrolytes, creatinine) 2-4 weeks after starting/adjusting RAAS inhibitors or diuretics 9

Maintenance Phase

Once BP is controlled:

• Follow-up every 3-6 months for stable patients
• Continue HBPM for ongoing monitoring and early detection of loss of control 5
• Annual laboratory testing (electrolytes, creatinine, lipids, glucose)
• Reassess cardiovascular risk periodically and adjust treatment intensity accordingly

Team-Based Care

A team-based care approach is recommended for all adults with hypertension 9. Effective teams may include:

• Physicians, nurse practitioners, physician assistants
• Pharmacists (medication management, adherence counseling)
• Nurses (BP monitoring, patient education)
• Community health workers (addressing social determinants)
• Dietitians (dietary counseling)

Telehealth strategies and electronic health record-based interventions improve BP control rates and should be utilized 9.

Common Pitfalls and How to Avoid Them

1. Inaccurate BP measurement: Always use proper technique with validated devices and appropriate cuff size. Confirm diagnosis with out-of-office monitoring.

2. Treating isolated office readings without confirmation: Avoid initiating or intensifying therapy based on single elevated readings. Obtain multiple measurements over time and consider HBPM/ABPM.

3. Undertreatment due to fear of adverse effects: The evidence strongly supports intensive BP lowering to <130/80 mm Hg. Orthostatic hypotension and other concerns should not prevent achieving goal BP in most patients 5.

4. Using hydrochlorothiazide instead of thiazide-like diuretics: Chlorthalidone and indapamide have superior cardiovascular outcomes and longer duration of action 10.

5. Combining ACE inhibitors with ARBs: This combination increases adverse events without additional benefit and should be avoided 4.

6. Failing to screen for secondary causes in resistant hypertension: Primary aldosteronism is present in up to 20% of resistant hypertension cases and is treatable 5, 10.

7. Not addressing medication adherence: Nonadherence is the most common cause of apparent treatment resistance. Use pill counts, pharmacy records, and motivational interviewing 12.

8. Delaying combination therapy in stage 2 hypertension: Initiating with 2 agents achieves control faster and improves outcomes 9.

9. Ignoring lifestyle modification: Pharmacotherapy alone is insufficient. Lifestyle changes are essential and produce additive BP reduction 5.

10. Inadequate follow-up: Monthly reassessment during titration and regular HBPM are critical for achieving and maintaining control 9.

Implementation Strategies

Multilevel, multicomponent implementation strategies are the most effective methods for BP control 5. Key elements include:

• Standardized BP measurement protocols in all clinical settings
• Electronic health record alerts for uncontrolled hypertension
• Patient registries to track control rates and guide quality improvement
• Single-pill combination therapy to improve adherence
• Home BP monitoring programs with telemonitoring support
• Pharmacist-led medication management services
• Community-based interventions addressing social determinants of health

The evidence strongly supports that achieving BP control to <130/80 mm Hg through intensive, guideline-concordant management reduces cardiovascular morbidity and mortality across diverse populations. Success requires accurate diagnosis, risk-stratified treatment, appropriate pharmacotherapy, sustained lifestyle modification, and systematic follow-up using team-based care models.